



ASX & Media Release

Patrys Presents at AACR Conference

Melbourne, Australia; 17 April, 2018: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce the presentation of new scientific data regarding its lead candidate, PAT-DX1, at this year's prestigious American Association for Cancer Research (AACR) Annual Meeting on April 14th – 18th 2018 in Chicago, Illinois.

The poster presented results from Dr. James Hansen's lab at the Yale School of Medicine in New Haven, Connecticut. Dr. Hansen is the inventor and primary investigator of Patrys' Deoxymab program. The poster, entitled "Deoxymab-1, a re-engineered DNA-damaging lupus autoantibody, shows promise in the treatment of DNA repair-deficient malignancies" is available at http://www.patrys.com/site/deoxymab-poster/AACR_2018.pdf.

The results presented in the poster reiterate previous findings that PAT-DX1 localizes to various tumors due to its attraction to DNA released by dying cancer cells, penetrates into cell nuclei, inhibits DNA repair, and kills cancer cells with defects in homology-directed repair (HDR). Furthermore, PAT-DX1 treatment reduced tumor growth and improved survival in an animal model of difficult to treat glioblastoma (brain cancer). The ability of PAT-DX1 to modulate the activity of other anti-cancer agents such as PARP inhibitors has been observed, and the exact mechanisms of these interactions are being further investigated.

"The AACR annual meeting is the most important conference for pre-clinical cancer globally, and attracts thousands of pharmaceutical industry and academic scientists and clinicians from around the world. It is an outstanding forum at which to update the research community on the exciting progress made with the PAT-DX1 program over the past year, and to initiate and progress research alliances," said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys.

About Deoxymab 3E10, PAT-DX1 and PAT-DX1-NP

Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP)



towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to significantly improve survival in an orthotopic model of glioblastoma. PAT-DX1 has also been shown to work synergistically with the approved PARP inhibitor, olaparib. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.

-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:

Ben Walsh
WE Buchan
P: +61 2 9237 2801
bwalsh@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.